Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

Eli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate. It could compete with CRISPR Therapeutics, a gene editing-focused biotech.